NCT02934763

Brief Summary

Opioid Induced Hyperalgesia (OIH) is an entity than has been demonstrated in healthy volunteers and in animal models. Is defined as an increase in the perception to painful stimuli, increasing the opioid requirements and diminishing the pain thresholds to stimuli. The apparition of OIH is also related to the exposure to opioids during surgery, depending of the dose, the time of exposition and the type of opioid. This condition can be modulated, specially in the perioperative context. It has been seen in healthy volunteers and in animal models, than the use of propranolol can modulate this phenomena, diminishing the postoperative requirements of analgesia. It is also unknown, the dose of propranolol required to modulate adequately OIH. The objective of this work is to evaluate the efficacy of propranolol in the modulation of opioid induced hyperalgesia, with lower postoperative requirements of analgesia rescue.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Oct 2016

Shorter than P25 for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 12, 2016

Completed
19 days until next milestone

Study Start

First participant enrolled

October 1, 2016

Completed
16 days until next milestone

First Posted

Study publicly available on registry

October 17, 2016

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

October 27, 2016

Status Verified

October 1, 2016

Enrollment Period

6 months

First QC Date

September 12, 2016

Last Update Submit

October 26, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative opioid use

    Dose of opioid required to manage pain adequately

    24 hours posterior to surgery

Secondary Outcomes (4)

  • Pain thresholds (heat)

    24 hours posterior to surgery

  • Pain thresholds (cold)

    24 hours posterior to surgery

  • Pain thresholds (tactile sensitivity)

    24 hours posterior to surgery

  • Temporal changes in pain sensibility

    24 hours posterior to surgery

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Saline solution by target controlled infusion

Drug: Saline

Propranolol at 5ng/ml target dose

ACTIVE COMPARATOR

Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml

Drug: Propranolol

Propranolol at 15ng/ml target dose

ACTIVE COMPARATOR

Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml

Drug: Propranolol

Interventions

propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals

Also known as: Beta blocker
Propranolol at 15ng/ml target dosePropranolol at 5ng/ml target dose
SalineDRUG

Saline as placebo

Also known as: Placebo
Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients scheduled for elective laparoscopic cholecystectomy
  • American Society of Anesthesiology Score (ASA) I-II

You may not qualify if:

  • Medical history of cardiac disease
  • Medical history of respiratory disease
  • Regular use of beta blockers
  • Known allergies to drugs used in the study
  • Known history of illicit drugs use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hyperalgesia

Interventions

PropranololAdrenergic beta-AntagonistsSodium Chloride

Condition Hierarchy (Ancestors)

Somatosensory DisordersSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic CompoundsAdrenergic AntagonistsAdrenergic AgentsNeurotransmitter AgentsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesPhysiological Effects of DrugsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 12, 2016

First Posted

October 17, 2016

Study Start

October 1, 2016

Primary Completion

April 1, 2017

Study Completion

May 1, 2017

Last Updated

October 27, 2016

Record last verified: 2016-10